Literature DB >> 12429636

Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.

Katarina Omholt1, Sofia Karsberg, Anton Platz, Lena Kanter, Ulrik Ringborg, Johan Hansson.   

Abstract

PURPOSE: Mutations in the ras genes often occur during tumorigenesis. In malignant melanoma, the most common ras alterations are N-ras codon 61 mutations. This study was aimed to measure the frequency of such mutations in a large series of paired primary and metastatic melanomas to determine their role in melanoma initiation and progression. EXPERIMENTAL
DESIGN: Seventy-four primary melanomas and 88 metastases originating from 54 of the primary tumors were screened for N-ras codon 61 mutations using single-strand conformation polymorphism and nucleotide sequence analyses.
RESULTS: Twenty-one of the 74 primary tumors (28%) had activating N-ras codon 61 mutations. From 20 of the mutated primary tumors, a total of 34 metastases were analyzed, and all but one showed the same mutation as the primary tumor from which they originated. The remaining 53 primary tumors and corresponding metastases (n = 54) were wild-type for N-ras codon 61. Analysis of the different growth phases of the mutated primary tumors showed that the mutations were already present in the radial growth phase. Mutations were also detected in tumor-associated nevi. N-ras codon 61 mutations were associated with a higher Clark level of invasion (P = 0.012) and a lower age at diagnosis (P = 0.042) but did not affect survival (P = 0.671).
CONCLUSIONS: This study shows that N-ras codon 61 mutations occur early in primary melanomas rather than in the metastatic stage and that once the mutations have occurred, they persist throughout tumor progression. This suggests that activated N-ras may be an attractive target for therapy in the subset of melanoma patients carrying such mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429636

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.

Authors:  Ozgecan Dulgar; Tugce Kutuk; Zeynep Eroglu
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

3.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

Authors:  O M Grbovic; A D Basso; A Sawai; Q Ye; P Friedlander; D Solit; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

4.  Wnt signaling potentiates nevogenesis.

Authors:  Jeff S Pawlikowski; Tony McBryan; John van Tuyn; Mark E Drotar; Rachael N Hewitt; Andrea B Maier; Ayala King; Karen Blyth; Hong Wu; Peter D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 5.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

6.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

Authors:  Keith T Flaherty; Sandra J Lee; Fengmin Zhao; Lynn M Schuchter; Lawrence Flaherty; Richard Kefford; Michael B Atkins; Philip Leming; John M Kirkwood
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

8.  Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.

Authors:  Heidi V N Küsters-Vandevelde; Jan E E Keunen; Pieter Wesseling; Marian A J Verdijk; Marjolijn J L Ligtenberg; Willeke A M Blokx
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

Review 9.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.